This HTML5 document contains 17 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/drugbank/drug/DB05445/identifier/pubchem-compound/
n10http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n4http://linked.opendata.cz/resource/drugbank/drug/DB05445/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n8http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05445
rdf:type
n5:Drug
n5:description
TA-NIC is a novel and proprietary vaccine in development as an aid to quitting smoking in motivated patients. TA-NIC is an immunotherapeutic vaccine similar in concept to TA-CD, designed to raise anti-nicotine antibodies. The antibodies bind to nicotine molecules in the patient's blood stream, reducing the rate and quantity of nicotine entry into the brain and thus reducing the positive reinforcement and addiction associated with nicotine and cigarette smoking. It is expected that the reduction of the positive reinforcement will in turn reduce the desire to smoke or use other tobacco products.
n5:generalReferences
# Goniewicz ML, Koszowski B, Czogala J, Zymelka A: [New prospects of nicotine dependence treatment--vaccines] Przegl Lek. 2006;63(10):1114-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17288232 # Cerny T: Anti-nicotine vaccination: where are we? Recent Results Cancer Res. 2005;166:167-75. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15648190 # Trial watch: Xenova's TA-NIC vaccine shows promise. Expert Rev Vaccines. 2004 Aug;3(4):386. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15270640 # Hagenbuch B, Meier PJ: Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest. 1994 Mar;93(3):1326-31. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8132774
n5:group
investigational
n5:indication
Investigated for use/treatment in tobacco dependence.
owl:sameAs
n10:DB05445
dcterms:title
TA-NIC
adms:identifier
n4:DB05445 n6:6675
n5:mechanismOfAction
Reduces nicotine entry into the brain and thus the positive reinforcement associated with smoking.
n5:synonym
Taurocholate Cholyltaurine Cholaic acid
n5:toxicity
Appears to be well-tolerated.
n5:proteinBinding
TA-NIC consists of nicotine conjugated to the carrier protein rCTB and an aluminium adjuvant.
n5:Molecular-Formula
n8:271B43DB-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n8:271B43DA-363D-11E5-9242-09173F13E4C5